Results 61 to 70 of about 3,595 (167)

Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus faecalis

European Journal of Case Reports in Internal Medicine, 2023
Infective endocarditis is a relatively uncommon infection that requires a high index of suspicion, which can sometimes delay its diagnosis. It requires several weeks of intravenous antibiotics, which traditionally requires long hospital stays ...
Francisco Javier Teigell Muñoz, María Mateos-González, Elsa Bernal-Hertfelder, Ana Sánchez de Torre, María García-Ferrón, Carmen de Cáceres Velasco, Coralia Bueno Muiño   +6 more
doaj   +1 more source

Prosthetic Mitral Valve Endocarditis due to Vagococcus fluvialis: A Case Report

Case Reports in Medicine, Volume 2026, Issue 1, 2026.
Infective endocarditis (IE) is an uncommon but life‐threatening disease, most frequently caused by Staphylococcus aureus, streptococci, and enterococci. Vagococcus fluvialis is a Gram‐stain positive coccus, phenotypically close to enterococci, and rarely identified in human infections due to diagnostic challenges.
Camille Le Guillou, Yvon Ruch, Florian Baquer, Pierre Boyer, Michel Kindo, Mircea Cristinar, Sebastien Brua, Paul Michel Mertes, Walid Oulehri, Amr A. Arafat   +9 more
wiley   +1 more source

The Role of ACE2 in SARS‐CoV‐2 Infection, Pathogenesis, and Antiviral Interventions

Journal of Medical Virology, Volume 97, Issue 12, December 2025.
ABSTRACT The devastating clinical, psychological, and economic impact of the COVID‐19 pandemic, caused by global spread of the second Severe Acute Respiratory Syndrome Coronavirus (SARS‐CoV‐2), has engendered a massive response from the scientific community to rapidly understand the biology of SARS‐CoV‐2 and to develop interventions to prevent ...
Michael A. McVoy, Apparao B. Kummarapurugu   +1 more
wiley   +1 more source

Dalbavancin Use in Vulnerable Patients Receiving Outpatient Parenteral Antibiotic Therapy for Invasive Gram-Positive Infections

Infectious Diseases and Therapy, 2019
Introduction Dalbavancin is approved for acute bacterial skin and skin structure infections (ABSSSIs) but offers a potential treatment option for complicated invasive gram-positive infections.
Jacqueline T. Bork, Emily L. Heil, Shanna Berry, Eurides Lopes, Rohini Davé, Bruce L. Gilliam, Anthony Amoroso   +6 more
doaj   +1 more source

Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series

Annals of Clinical Microbiology and Antimicrobials, 2022
Background Dalbavancin is a semisynthetic antibiotic used as an alternative to vancomycin for skin infections and osteomyelitis. Its long half-life decreases length of hospitalizations.
Connor Evins, Harrison Lancaster, Amanda E. Schnee   +2 more
doaj   +1 more source

Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital

Microbiology Spectrum, 2023
Dalbavancin is a second-generation lipoglycopeptide antibiotic with activity against Gram-positive organisms. Dalbavancin is Food and Drug Administration (FDA)-approved for acute bacterial skin and soft tissue infections (ABSSTIs).
Richard Lueking, Wenjing Wei, Norman S. Mang, Jessica K. Ortwine, Jessica Meisner   +4 more
doaj   +1 more source

Antibiotic Resistance: A Genetic and Physiological Perspective

MedComm, Volume 6, Issue 11, November 2025.
The development of resistance to antimicrobials and their historical progression are depicted in this graphic. It draws attention to important biochemical, physiological, and genetic factors that contribute to AMR, such as the transmission of genes, the development of biofilms, and the inactivation of antibiotics.
Rania G. Elbaiomy, Ahmed H. El‐Sappah, Rong Guo, Xiaoling Luo, Shiyuan Deng, Meifang Du, Xiaohong Jian, Mohammed Bakeer, Zaixin Li, Zhi Zhang   +9 more
wiley   +1 more source

Strategies to stabilize dalbavancin in aqueous solutions: Section 4—identification of heat degradation products in 2-hydroxypropyl-β-cyclodextrin and divalent metal ion solutions at pH 4.5 and 7.0

AAPS Open, 2023
Heat stress studies have been conducted in support of developing a heat-stable liquid solution of dalbavancin. The degradation products that form in heat-stressed buffered dalbavancin solutions have been identified, including the known major degradation ...
Sardar M. Jakaria, David E. Budil, James Murtagh   +2 more
doaj   +1 more source

P-1102. Real-World Effectiveness of Dalbavancin for Invasive Gram-Positive Bacterial Infections

American Journal of Health-System Pharmacy
Background Emerging data suggest dalbavancin (DAL) may be used in complicated infections including bacteremia, prosthetic joints, osteomyelitis, and endovascular infections.
PharmD Jake Crocker, PharmD Caroline Derrick, PharmD MS Fidsa Julie Ann Justo, PharmD P. Brandon Bookstaver, PharmD PhD Ismaeel Yunusa, Pharm. Bruce M. Jones, PharmD Bcps Bcidp Bryan White, MD Joseph Sassine, PharmD Madeline Belk, PharmD Morgan Pizzuti   +9 more
semanticscholar   +1 more source

Role of Extracellular DNA in Dalbavancin Activity against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms in Patients with Skin and Soft Tissue Infections

Microbiology Spectrum, 2022
Methicillin-resistant Staphylococcus aureus (MRSA) has become the leading cause of skin and soft tissue infections (SSTIs). Biofilm production further complicates patient treatment, contributing to increased bacterial persistence and antibiotic tolerance.
Francesca Sivori, Ilaria Cavallo, Daniela Kovacs, Maria Guembe, Isabella Sperduti, Mauro Truglio, Martina Pasqua, Grazia Prignano, Arianna Mastrofrancesco, Luigi Toma, Fulvia Pimpinelli, Aldo Morrone, Fabrizio Ensoli, Enea Gino Di Domenico   +13 more
doaj   +1 more source